Eligible patients taking Camzyos in the maintenance phase now only require twice-yearly echocardiogram monitoring. The Food and Drug Administration (FDA) has updated the labeling for Camzyos ® ...
Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label ...
FDA lowers echo monitoring to every 6 months for select Camzyos patients in maintenance phase. Camzyos label update removes prior contraindications with certain CYP inhibitors. See the trading ...
Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
Cytokinetics aims to compete with a Bristol Myers Squibb heart drug projected to become a blockbuster seller, and the company’s value proposition is that its drug candidate has a potential safety edge ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with ...
SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback